Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Humira adalimumab: Phase III data; marketed

February 2, 2004 8:00 AM UTC

Researchers published data from the double-blind, Phase III STAR trial in 636 patients that showed that there were no significant differences in adverse event rates between patients given 40 mg Humira...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article